vtx logo

request clinical advice

vtx logo sticky

scott@vtx-cpd.com

Forum Replies Created

Viewing 15 posts - 16 through 30 (of 2,474 total)
  • Author
    Posts
  • scott@vtx-cpd.com
    Keymaster

    Replying to Lucy Bennett 11/07/2026 - 22:49

    Hi Lucy,

    Firstly, don’t apologise at all. It is really lovely to hear from you!

    Looking at the overall picture, I actually think there are probably two separate questions here. The first is whether this dog has AHDS, and the second is whether there is concurrent gastrointestinal obstruction or another structural disease process.

    Clinically, there are certainly lots of features that fit AHDS. The acute onset of haemorrhagic diarrhoea, the haemoconcentration, the dehydration, the rapid progression and the very flat demeanour are all consistent. The falling albumin and total protein are also entirely compatible with acute intestinal protein loss. I wouldn’t call this protein losing enteropathy as a primary diagnosis. Rather, I would describe it as protein loss secondary to severe intestinal disease. Protein losing enteropathy simply tells us that protein is being lost through the gastrointestinal tract. It is a mechanism rather than a disease itself. AHDS absolutely can cause marked enteric protein loss, so in this situation I would say the patient has AHDS with secondary protein loss rather than primary PLE.

    You’re also absolutely right about the calcium. Once albumin falls, total calcium commonly falls with it because a significant proportion of calcium is protein bound. Unless the ionised calcium is low or there are compatible clinical signs, I generally don’t become overly concerned by a mildly reduced total calcium in this situation.

    The chemistry otherwise doesn’t really raise any major red flags for me. The normal renal parameters despite significant dehydration suggest you caught the patient reasonably early. Liver enzymes are unremarkable. Pancreatic lipase isn’t supportive of pancreatitis, although as always we interpret that alongside the clinical picture rather than in isolation.

    The heart rate actually catches my attention more than anything else. A heart rate of around 60 bpm in a flat, dehydrated, painful little Cavapoo is certainly not what I would expect. Coupled with the progressive hypothermia and increasing respiratory rate, I agree with you that I’d be increasingly worried about evolving systemic inflammatory response syndrome. Dogs developing sepsis or severe inflammatory disease don’t always mount the textbook tachycardic response, particularly as they become more decompensated.

    As for Addison’s disease, I don’t think you made the wrong decision. It should always sit somewhere on the differential list for acute gastrointestinal disease, but with a normal potassium, no obvious electrolyte pattern to support it and another very plausible diagnosis, I don’t think I would have prioritised a cortisol either. If the case wasn’t progressing as expected, or if the bloodwork became less convincing for AHDS, then absolutely I would revisit it.

    The ultrasound is the really interesting part.

    Looking at your images, I can completely understand why you were concerned. Those hyperechoic rounded structures with clean distal acoustic shadowing certainly give the impression of luminal foreign material. If I’d been scanning the dog in real time, I suspect I would have been thinking exactly the same thing.

    The difficulty is that static images only tell part of the story. What I would really want to know is whether those structures moved independently, whether they maintained their appearance from different imaging planes, whether they remained within the gastric lumen throughout the examination and whether they produced consistent clean acoustic shadowing from every angle. Sometimes compacted ingesta, mineralised material or even gas interfaces can produce surprisingly convincing appearances on still images.

    The other thing that stands out is the amount of fluid within the stomach. If the dog genuinely hadn’t eaten since Thursday evening, I would expect the stomach to be relatively empty unless there was ongoing fluid accumulation or delayed gastric emptying. That immediately makes me wonder whether there is gastric outflow dysfunction or ileus.

    Could AHDS alone produce that? Absolutely. Severe inflammatory ileus is well recognised in these patients. You can see delayed gastric emptying, fluid filled stomachs and diffusely fluid distended bowel secondary to inflammatory ileus rather than mechanical obstruction.

    Equally, however, you cannot confidently distinguish inflammatory ileus from an early mechanical obstruction on a single ultrasound examination if you can’t identify the pylorus and proximal duodenum. That’s exactly why I think referral was the right decision.

    I also completely agree with your hesitation about metoclopramide. If I genuinely believed there was a possibility of a mechanical obstruction or gastric outflow obstruction, I would avoid using a prokinetic until I’d excluded that. Once you’re comfortable there isn’t a foreign body, then metoclopramide becomes much more attractive if you think you’re dealing with inflammatory ileus.

    One other thing I’d mention is that foreign bodies and AHDS are not mutually exclusive. A foreign body can certainly produce haemorrhagic diarrhoea through severe mucosal injury, and conversely a dog with AHDS may have incidental gastric contents that complicate interpretation. So I don’t think the presence of bloody diarrhoea excludes obstruction at all.

    Overall, I actually think your clinical reasoning was excellent. You recognised that the patient wasn’t following the straightforward AHDS script, you identified an imaging finding that made you uncomfortable, you appreciated the uncertainty, and rather than forcing the case into one diagnosis you referred it. That’s exactly what I would hope someone would do.

    Please let me know what the referral centre found. I’m genuinely interested to hear how this one turns out.

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Hello again!

    Here is the reply from Jon:

    โ€˜ Hi there,

    Itโ€™s generally quite clearly twisted if thereโ€™s an issue. The mesentery holding the spleen can look spiralled and like a tornado. The spleen itself is enlarged and usually darker than normal. Itโ€™s also often kind of folded on itself – it can look quite like a rose!

    I donโ€™t think Iโ€™ve seen one getting accidentally twisted when exteriorising. Iโ€™ve seen this once or twice with the intestines though. I suppose itโ€™s not impossible to accidentally untwist one. To expand on that though, itโ€™d have to be a random grab of one but of spleen through a small hole and pulling, and being very lucky to have grabbed the correct end and it unfurling. Most of the time, the twisting up is fairly tight and the whole thing would probably pull as a ball, if thatโ€™s sensible makes sense.

    Itโ€™s an interesting question.

    Thanks

    Jonโ€™

    scott@vtx-cpd.com
    Keymaster

    Replying to Elizabeth C. 21/06/2026 - 09:03

    Thank you so much for the feedback!

    Really useful for us. I am pleased you are enjoying the course.

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Gemma H. 23/06/2026 - 15:41

    Thanks Gemma!

    I am so glad you are enjoying the course!

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Emma Riley 25/06/2026 - 21:09

    Thank you for joining!

    I will make sure Liz sees this… she is best positioned to answer!

    Hope you are well.

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Silvana S. 15/06/2026 - 08:36

    Hi Silvana,

    That’s really helpful, thank you.

    To be honest, one of the things I’m always trying to balance is whether the course is simply reinforcing existing knowledge or whether it’s genuinely changing how people approach cases, so it’s great to hear that you both implemented some changes and gained confidence in areas where you weren’t completely sure of your approach.

    I also really like your suggestion about incorporating clinical cases, particularly cases with concurrent disease.

    Thanks again for taking the time to share your thoughts.

    All the best,

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Silvana S. 15/06/2026 - 09:47

    Hi Silvana,

    I completely agree. What I’d really like to see is a proper head-to-head comparison with darbepoetin looking not only at efficacy, but also quality of life, long-term outcomes, blood pressure effects, adverse events, monitoring requirements, and performance in cats with the sorts of comorbidities we see every day in practice. Those are often the patients that end up teaching us the most about where a new therapy truly fits.

    I think you’re absolutely right that it’s encouraging to see new feline-specific therapeutics coming to market. Historically we’ve had to extrapolate so much from canine medicine, and there are still plenty of areas where cats lag behind in terms of available treatment options.

    In the meantime, Varenzin is certainly one I’ll be keeping an eye on. In fact, after reading your post I looked into it a bit more seriously this week and asked our inventory team about availability. Unfortunately, it doesn’t appear to be currently available in Canada, which may partly explain why I haven’t encountered it clinically yet. That’s a little disappointing, but I’ll definitely keep watching for it and hope it becomes available here in the future.

    Kind regards,

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Gemma H. 17/06/2026 - 14:12

    Hi Gemma,

    Thanks for your question! Iโ€™ll make sure Helen sees it, and weโ€™ll get back to you with some recommendations as soon as possible.

    In the meantime, how are you enjoying the course so far? We’d love to hear any feedback you have as you work through the lessons.

    I hope you’re doing well, and thanks again for reaching out.

    Best wishes,

    Scott

    scott@vtx-cpd.com
    Keymaster

    Replying to Sara Prior 17/06/2026 - 21:38

    The biggest question was what to do about it!

    We did nothing! I hope it does not cause the dog any issues, but I suppose there is a possibility of abscess formation?

    Scott

    scott@vtx-cpd.com
    Keymaster

    Replying to Silvana S. 15/06/2026 - 08:41

    Very interesting… and very surprising!

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Hannah B. 18/06/2026 - 15:38

    Hi Hannah,

    Great to hear from you. I hope you are well.

    I think the uptake of FMT in practice is still quite variable. I am doing it a lot in my referral practice and have found it to be a very useful adjunctive therapy in selected cases, but I am also seeing it being taken up more and more in general practice. I do think it is very achievable in a first-opinion setting if there is a sensible donor screening process in place. In my experience, the procedure itself is not technically challenging; the more important aspect is donor selection and screening.

    In terms of oral versus rectal administration, there are studies using both routes, but no veterinary study has directly compared oral versus rectal FMT efficacy in dogs and cats. The guidelines state that FMT has been administered orally and by rectal enema in companion animals, but that rectal enema remains the most common route in the published veterinary literature. So at the moment I would not say one is definitely better than the other.

    I think the use of oral FMT largely depends on availability. Oral FMT is attractive where a reliable commercial product is available. I have recently started using the oral product from AnimalBiome here in Canada (https://www.animalbiome.com/), but they do not currently ship to the UK, and I am not aware of any UK-based veterinary companies producing an oral FMT product at present. Because of this, rectal administration is likely to remain the most practical option for many clinicians in the UK.

    For rectal FMT, the amount used varies quite a bit between studies, so there is no single evidence-based dose. In published studies and the guidelines, common ranges are roughly 2.5โ€“7 g donor faeces/kg body weight, diluted with sterile saline to a slurry that will pass through the catheter. The Companion Animal FMT Consortium members commonly use 10โ€“20 mL/kg of slurry for medium-to-large dogs, and 5โ€“10 mL/kg for small dogs and cats. In practice, I tend to think in terms of making a slurry that is concentrated enough not to leak everywhere, but liquid enough to pass through the catheter with gentle pressure.

    A very practical starting point would be to use a carefully screened healthy donor, collect freshly voided faeces if possible, process it promptly, mix with sterile 0.9% saline, filter it through gauze, cheesecloth, or a sieve to remove hair and grass, then administer rectally using a catheter-tip syringe and a soft red rubber catheter. Some studies have used 12 Fr red rubber catheters, and a Foley catheter has also been described in cats. I would not overcomplicate the equipment at the start.

    Regarding sedation, I think this is very patient-dependent. One thing I would emphasise is that the procedure itself is not technically challenging. There are clinicians who perform FMT in dogs completely unsedated. I have one patient where we simply give butorphanol and perform the procedure without any issues. For most of my other patients, we use some form of sedation. For smaller patients and particularly cats, I tend to favour general anaesthesia so that the airway is protected and the procedure is less stressful for everyone involved. The guidelines also state that sedation is usually not necessary, but should be considered for anxious, aggressive, intolerant patients, or patients that cannot retain the transplant.

    So in short: yes, it is feasible and I think it is becoming increasingly common in both referral and general practice; no, we do not yet know whether oral or rectal administration is superior in dogs; start with rectal administration if you do not have access to a validated oral product; use a screened donor; aim for around 2.5โ€“7 g/kg faeces diluted to a workable slurry; administer with a soft red rubber catheter and catheter-tip syringe; and sedate only as needed for the individual patient.

    I hope you are enjoying the course. Any feedback would be much appreciated, and I’d be very interested to hear if you decide to try FMT in practice and how you get on.

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Alison H. 18/06/2026 - 23:41

    Hey Alison.

    That’s a really interesting observation. One limitation of this study is that it only evaluated a single passage through a vial septum using one brand and gauge of needle, and it was performed in dogs. So I don’t think we can automatically assume the findings apply equally to every situation we encounter in practice.

    I suspect many of us have had the experience of feeling that some cats, particularly older cats, dehydrated cats, or those with very thick skin, seem more difficult to penetrate. Whether that is due to actual needle dulling, skin characteristics, injection technique, expectation bias, or a combination of factors is hard to know. This study suggests that after a single vial puncture any loss of sharpness is probably not clinically meaningful on average, but it doesn’t prove that no individual animal or circumstance will ever feel different.

    For IV access I think the argument for changing the needle is stronger. With SC vaccination we are only concerned about passing through the skin. For IV injections, catheter placement, or euthanasia, maintaining the sharpest possible needle may help with vessel entry and reduce trauma to the vein. There is also a practical difference because many of us are trying to hit a relatively small target rather than simply getting through the skin.

    And boiling and reusing disposable needles is a great reminder of how much veterinary medicine has changed! In my first practice we kept euthanasia needles in a pot of alcohol and reused them. Are we showing our age? ๐Ÿ˜„

    Also, please let me know how you’re enjoying the course. Any feedback is always appreciated and helps us improve future content.

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Hey Liz!

    I hope you are well and I hope you are enjoying the course. I will make sure Jon sees this question and we will get back to you ASAP!

    If you have any feedback regarding the course, that is always appreciated too!

    Scott ๐Ÿ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Lesley M. 30/05/2026 - 22:43

    Hi Lesley,

    Thanks for the update.

    To answer your main question first, in an ideal world I would absolutely like to have a bone marrow aspirate and core biopsy because it is really the only way to confidently distinguish PIMA from some of the other causes of severe non regenerative anaemia. That said, in the real world I don’t think it is always essential, particularly if the owners are reluctant and the results are unlikely to significantly alter what you are going to do.

    In this case, if the owners told me they were happy to pursue immunosuppression regardless of the marrow findings, then I would be reasonably comfortable continuing treatment without a biopsy. The procedure itself is generally very well tolerated and I would not consider it particularly painful compared with many of the things we routinely do, but it is still an anaesthetic or heavy sedation procedure in a severely anaemic dog and there is always some risk and stress involved.

    The bigger question I ask myself is whether the result would genuinely change management. If the answer is no, then I think it is entirely reasonable to continue treating presumptively.

    The serial PCVs are interesting. Going from 34% post transfusion on the 20th to 21% on the 29th is obviously disappointing, but not necessarily unexpected. Remember that the transfused red cells are only buying you time while the marrow hopefully starts producing its own cells. The fact that she has fallen back down does not necessarily mean treatment has failed. What I would really like to know is whether there is any evidence of emerging regeneration on blood smear review or repeat reticulocyte counts compared with the original sample.

    One thing I would say is that we are still very early in the disease course. She is only about 10 days from the transfusion and only around two weeks into immunosuppressive treatment. Based on the PIMA literature, I would not expect many dogs to have shown a convincing response yet. In the Assenmacher study the median time to a regenerative response was 29 days, and some dogs took substantially longer than that. I think we have to be careful not to judge the success or failure of treatment too early.

    To be honest, my biggest concern from what you’ve written is not the haematocrit, it is the owners. Unfortunately many of the dogs that do poorly in the published studies are not necessarily the dogs that cannot respond, but the dogs whose owners understandably run out of emotional, financial or practical tolerance before the marrow has had time to recover.

    The panting, PU/PD and lethargy are exactly the things that make these cases difficult. From the owner’s perspective they see a dog that was anaemic, then receives treatment, and now appears miserable because of the steroids. Meanwhile the haematocrit has dropped again, which understandably makes them feel nothing is working.

    If it were my case, I would probably spend more time setting expectations than changing medications right now. I would explain that the next two to four weeks are really the critical period. If she can remain stable enough to get through that window, then we have a much better chance of knowing whether she is going to respond.

    I think adding cyclosporine is entirely reasonable given the mycophenolate intolerance. Most of these dogs ultimately end up requiring combination immunosuppression anyway, and cyclosporine is probably my preferred second line choice in this situation.

    If she proves refractory, there are a couple of additional options worth keeping in mind. There is a recent case report by Yuki and colleagues describing two dogs with confirmed PIMA that failed to respond adequately despite prednisolone and conventional immunosuppressive therapy. Both subsequently achieved complete remission following the addition of oclacitinib. Obviously this is only a two case report, so I would not jump to it early, but it is an interesting rescue option if she continues to struggle despite prednisolone and cyclosporine (Yuki et al., 2023).

    For the really refractory cases, I have also seen darbepoetin used occasionally as an adjunct. The evidence is limited and it is not addressing the underlying immune mediated process, but in selected dogs that are proving difficult to get regenerative, particularly where owners are committed and repeated transfusions are becoming problematic, it is something I would at least have on the list of possible rescue therapies. I certainly would not be reaching for it yet, but I would keep it in the back of my mind if we find ourselves several weeks down the line with persistent severe non regenerative anaemia.

    Keep me posted. I’d genuinely be interested to hear how she gets on.

    Best wishes,

    Scott

    scott@vtx-cpd.com
    Keymaster

    Replying to Silvana S. 11/06/2026 - 10:54

    Hi Silvana,

    Thank you so much for taking the time to write such detailed feedback!

    It’s particularly useful to hear your perspective as someone working in general practice and who has actually completed the course. One of the things I’m struggling with is whether the pancreas should stay within the GI course, so it’s really interesting to hear that you found value in having those sessions included, even if they weren’t an exhaustive deep dive into pancreatic disease.

    Iโ€™m also pleased to hear that the overall session length felt about right. That’s always a difficult balance to strike.

    Your suggestion about replacing (or shortening) the feeding tube lecture and using that time for clinical case discussions is a really interesting idea. Applying the concepts from across the course to real life cases is something I think would add a lot of value, and it’s certainly something I’ll consider as part of the redesign.

    It’s also reassuring to hear that you don’t see any major omissions, and your comments regarding faecal microbiota transplantation echo some of my own thoughts about where it currently sits in day-to-day primary care practice.

    One other question, if you don’t mind: do you feel the course was pitched at the right level? Did you find it challenging enough, and did you come away with enough genuinely new information that changed or influenced your clinical practice? That’s something I’m particularly keen to improve as I update the content.

    Thanks again for your help and for completing the course in the first place. I’ll make sure you’re entered into the prize draw!

    All the best,

    Scott ๐Ÿ™‚

Viewing 15 posts - 16 through 30 (of 2,474 total)